AstraZeneca Gets CDSCO Nod to Market Durvalumab for New Cancer Indications in India

Unknown Apr 02, 2026 1,150 Views

AstraZeneca Pharma India Ltd. has received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) to import and market Durvalumab (Imfinzi) for additional cancer indications. The move expands the drug’s therapeutic reach and reinforces AstraZeneca’s commitmen...